Skip to main content

Table 1 Clinical characteristics of GC patients in the training and validation set

From: A novel immune-related lncRNA pair signature for prognostic prediction and immune response evaluation in gastric cancer: a bioinformatics and biological validation study

Clinical features

Level

Overall

Training

Validation

Statistical P-value

Samples

 

303

212

91

 

Survival status (%)

Alive

177 (58.4)

121 (57.1)

56 (61.5)

0.552

 

Dead

126 (41.6)

91 (42.9)

35 (38.5)

 

Age (%)

 < 65

134 (44.2)

97 (45.8)

37 (40.7)

0.489

 

 >  = 65

169 (55.8)

115 (54.2)

54 (59.3)

 

Sex (%)

Female

112 (37.0)

75 (35.4)

37 (40.7)

0.457

 

Male

191 (63.0)

137 (64.6)

54 (59.3)

 

pStage (%)

I/II

138 (45.5)

92 (43.4)

46 (50.5)

0.308

 

III/IV

165 (54.5)

120 (56.6)

45 (49.5)

 

pT (%)

T1

12 (4.0)

11 (5.2)

1 (1.1)

0.265

 

T2

63 (20.8)

42 (19.8)

21 (23.1)

 
 

T3

148 (48.8)

100 (47.2)

48 (52.7)

 
 

T4

80 (26.4)

59 (27.8)

21 (23.1)

 

pN (%)

N0

93 (30.7)

67 (31.6)

26 (28.6)

0.566

 

N1

81 (26.7)

57 (26.9)

24 (26.4)

 
 

N2

65 (21.5)

41 (19.3)

24 (26.4)

 
 

N3

64 (21.1)

47 (22.2)

17 (18.7)

 

pM (%)

M0

282 (93.1)

197 (92.9)

85 (93.4)

1

 

M1

21 (6.9)

15 (7.1)

6 (6.6)

 

Grade (differentiated, %)

Well

7 (2.3)

7 (3.3)

0 (0.0)

0.19

 

Moderately

100 (33.0)

74 (34.9)

26 (28.6)

 
 

Poorly

188 (62.0)

126 (59.4)

62 (68.1)

 
 

Undifferentiated

8 (2.6)

5 (2.4)

3 (3.3)

 
  1. * The statistical differences between two groups were tested by χ2 or Fisher exact tests, if appropriate. pT: pathological T stage. pN: pathological N stage. pM: pathological M stage